Encouraged by the preclinical results, we are initiating a phase I clinical trial, Intraventricular T cell receptor transgenic T cell therapy to treat glioblastoma (INVENT4GB)69, to assess the feasibility and safety of intravenous and intracerebroventricular CD4+/CD8+ PTPRZ1-TCR-T cell therapy in patients with recurrent glioblastoma. Here, CD4 is linked to glioblastoma.